-+ 0.00%
-+ 0.00%
-+ 0.00%

We're Keeping An Eye On Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Rate

Simply Wall St·11/17/2026 10:38:47
Listen to the news

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

Given this risk, we thought we'd take a look at whether Pyxis Oncology (NASDAQ:PYXS) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

How Long Is Pyxis Oncology's Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. In September 2026, Pyxis Oncology had US$56m in cash, and was debt-free. Looking at the last year, the company burnt through US$71m. So it had a cash runway of approximately 9 months from September 2026. That's quite a short cash runway, indicating the company must either reduce its annual cash burn or replenish its cash. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
NasdaqGS:PYXS Debt to Equity History November 17th 2026

See our latest analysis for Pyxis Oncology

How Well Is Pyxis Oncology Growing?

In the last twelve months, Pyxis Oncology kept its cash burn steady. But the good news is that its operating revenue showed verdant growth, up 291%. We think it is growing rather well, upon reflection. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Pyxis Oncology To Raise More Cash For Growth?

Pyxis Oncology seems to be in a fairly good position, in terms of cash burn, but we still think it's worthwhile considering how easily it could raise more money if it wanted to. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Pyxis Oncology's cash burn of US$71m is about 42% of its US$169m market capitalisation. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful capital raising.

So, Should We Worry About Pyxis Oncology's Cash Burn?

Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Pyxis Oncology's revenue growth was relatively promising. Summing up, we think the Pyxis Oncology's cash burn is a risk, based on the factors we mentioned in this article. Taking a deeper dive, we've spotted 4 warning signs for Pyxis Oncology you should be aware of, and 2 of them are concerning.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)